Shares of ABIVAX Société Anonyme (ABVX) are down over 40% from their 52-week high of $14.16, recorded last July, to trade around $7.65.
This clinical-stage biotechnology company is focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. Its lead drug candidate is Obefazimod, being developed for the treatment of moderately to severely active ulcerative colitis (UC). Obefazimod is designed to enhance the expression of miR-124 and stabilize the immune response by downregulating key proteins associated with inflammation, such as IL-6 and TNF-alpha.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com